Comparative effectiveness of pembrolizumab vs. nivolumab in patients with recurrent or advanced NSCLC

The efficacies of pembrolizumab and nivolumab have never been directly compared in a real-world study. Therefore, we sought to retrospectively evaluate the objective response rate (ORR) and the progression-free survival (PFS) of patients with recurrent or advanced non-small cell lung cancer (NSCLC)...

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Pengfei, Li, Ruixin, Huang, Ziwei, Wu, Zhaozhen, Tao, Haitao, Zhang, Sujie, Hu, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7403144/
https://www.ncbi.nlm.nih.gov/pubmed/32753702
http://dx.doi.org/10.1038/s41598-020-70207-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7403144/
https://www.ncbi.nlm.nih.gov/pubmed/32753702
http://dx.doi.org/10.1038/s41598-020-70207-7

Ejemplares similares